Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFα, improves health-related quality of life in patients with moderate to severe Crohn’s disease

Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFα, improves health-related quality of life in patients with moderate to severe Crohn’s disease

Bibliographic Details
Main Authors: Rutgeerts, Paul, Schreiber, Stefan, Feagan, Brian, Keininger, Dorothy L., O’Neil, Liz, Fedorak, Richard N.
Format: Online
Language:English
Published: Springer-Verlag 2007
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2225995/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2225995/

Similar Items